References
- Ang GY, Yu CY, Subramaniam V, Abdul Khalid MIH, Tuan Abdu Aziz TA, Johari James R, Ahmad A, et al. 2016. Detection of CYP2C19 genetic variants in malaysian orang asli from massively parallel sequencing data. PLoS One 11:e0164169.
- Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265.
- Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, et al. 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98:19–24.
- Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391.
- Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. 2013. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 22:555–558.
- Ma Q, Lu AY. 2011. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63:437–459.
- Rosdi RA, Mohd Yusoff N, Ismail R, Soo Choon T, Saleem M, Musa N, Yusoff S, et al. 2016. High allele frequency of CYP2C9*3 (rs1057910) in a Negrito's subtribe population in Malaysia; aboriginal people of Jahai. Ann Hum Biol 43:445–450.
- Teh LK, Subramaniam V, Tuan Abdu Aziz TA, Lee LS, Ismail MI, Yu CY, Ang GY, et al. 2016. Systematic characterization and comparison of the CYP2C9 variability of the Orang Asli in Malaysia with 12 populations. Drug Metab Pharmacokinet 31:304–313.
- Thummel KE, Wilkinson GR. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430.
- Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, et al. 2013. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics 43:11.10.1–33.
- Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W, et al. 2013. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clin Ther 35:1762–1769.
- Yu CY, Ang GY, Subramaniam V, Johari James R, Ahmad A, Abdul Rahman T, Mohd Nor F, et al. 2017. Inference of the genetic polymorphisms of CYP2D6 in six subtribes of the malaysian orang asli from whole-genome sequencing data. Genet Test Mol Biomarkers 21:409–415.
- Yusoff NM, Saleem M, Nagaya D, Yahaya BH, Rosdi RA, Moosa N, Ismail R, Tan SC. 2015. Cross-ethnic distribution of clinically relevant CYP2C19 genotypes and haplotypes. J Pharmacogenomics Pharmacoproteomics 6:147.
- Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeutics 138:103–141.
- Zhou SF, Xue CC, Yu XQ, Li C, Wang G. 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710.